Universal influenza vaccines: Shifting to better vaccines

Vaccine

Volumn 34, Issue 26, 2016, Pages 2926-2933

  Berlanda Scorza, Francesco ^a   Tsvetnitsky, Vadim ^a,b   Donnelly, John J ^a  

^a PATH   (United States)

^b INTERNATIONAL AIDS VACCINE INITIATIVE   (United States)

Author keywords

Chimeric hemagglutinin; Heterosubtypic immunity; Influenza vaccines; Universal vaccines

Indexed keywords

HEMAGGLUTININ; INACTIVATED VIRUS VACCINE; INFLUENZA VACCINE; MATRIX PROTEIN; MATRIX PROTEIN M2E; MESSENGER RNA; NUCLEOPROTEIN; SYNTHETIC PEPTIDE; UNCLASSIFIED DRUG; VIRUS LIKE PARTICLE VACCINE; VIRUS VECTOR; DNA VACCINE; IMMUNOLOGICAL ADJUVANT; INFLUENZA VIRUS HEMAGGLUTININ; RECOMBINANT VACCINE;

ARTICLE; CROSS PROTECTION; DNA VECTOR; DRUG TARGETING; HUMAN; INFLUENZA; INFLUENZA VACCINATION; INFLUENZA VIRUS; PANDEMIC INFLUENZA; PRIORITY JOURNAL; SEASONAL INFLUENZA; T LYMPHOCYTE; ANIMAL; CLINICAL TRIAL (TOPIC); IMMUNOLOGY; INFLUENZA, HUMAN; MEDICAL RESEARCH; ORTHOMYXOVIRIDAE; ORTHOMYXOVIRIDAE INFECTIONS; TRENDS;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; BIOMEDICAL RESEARCH; CLINICAL TRIALS AS TOPIC; HEMAGGLUTININ GLYCOPROTEINS, INFLUENZA VIRUS; HUMANS; INFLUENZA VACCINES; INFLUENZA, HUMAN; ORTHOMYXOVIRIDAE; ORTHOMYXOVIRIDAE INFECTIONS; VACCINES, DNA; VACCINES, SYNTHETIC;

EID: 84962460823     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2016.03.085     Document Type: Article

References (44)

1. Cotter C.R., Jin H., Chen Z. A single amino acid in the stalk region of the H1N1pdm influenza virus HA protein affects viral fusion, stability and infectivity. PLOS Pathog 2014, 10:e1003831. 10.1371/journal.ppat.1003831.
2. Nair H., Brooks W.A., Katz M., Roca A., Berkley J.A., Madhi S.A., et al. Global burden of respiratory infections due to seasonal influenza in young children: a systematic review and meta-analysis. Lancet (Lond, Engl) 2011, 378:1917-1930. 10.1016/S0140-6736(11)61051-9.
3. Murray C.J.L., Lopez A.D., Chin B., Feehan D., Hill K.H. Estimation of potential global pandemic influenza mortality on the basis of vital registry data from the 1918-20 pandemic: a quantitative analysis. Lancet 2006, 368:2211-2218. 10.1016/S0140-6736(06)69895-4.
4. Brooks W.A., Goswami D., Rahman M., Nahar K., Fry A.M., Balish A., et al. Influenza is a major contributor to childhood pneumonia in a tropical developing country. Pediatr Infect Dis J 2010, 29:216-221. 10.1097/INF.0b013e3181bc23fd.
5. Nabel G.J., Fauci A.S. Induction of unnatural immunity: prospects for a broadly protective universal influenza vaccine. Nat Med 2010, 16:1389-1391. 10.1038/nm1210-1389.
6. Dreyfus C., Laursen N.S., Kwaks T., Zuijdgeest D., Khayat R., Ekiert D.C., et al. Highly conserved protective epitopes on influenza B viruses. Science 2012, 337:1343-1348. 10.1126/science.1222908.
7. Corti D., Voss J., Gamblin S.J., Codoni G., Macagno A., Jarrossay D., et al. A neutralizing antibody selected from plasma cells that binds to group 1 and group 2 influenza A hemagglutinins. Science 2011, 333:850-856. 10.1126/science.1205669.
8. Yassine H.M., Boyington J.C., McTamney P.M., Wei C.-J., Kanekiyo M., Kong W.-P., et al. Hemagglutinin-stem nanoparticles generate heterosubtypic influenza protection. Nat Med 2015, 21:1065-1070. 10.1038/nm.3927.
9. Impagliazzo A., Milder F., Kuipers H., Wagner M., Zhu X., Hoffman R.M.B., et al. A stable trimeric influenza hemagglutinin stem as a broadly protective immunogen. Science 2015, 349:1301-1306. 10.1126/science.aac7263.
10. Krammer F., Jul-Larsen A., Margine I., Hirsh A., Sjursen H., Zambon M., et al. An H7N1 influenza virus vaccine induces broadly reactive antibody responses against H7N9 in humans. Clin Vaccine Immunol 2014, 21:1153-1163. 10.1128/CVI.00272-14.
11. Turley C.B., Rupp R.E., Johnson C., Taylor D.N., Wolfson J., Tussey L., et al. Safety and immunogenicity of a recombinant M2e-flagellin influenza vaccine (STF2.4xM2e) in healthy adults. Vaccine 2011, 29:5145-5152. 10.1016/j.vaccine.2011.05.041.
12. Wohlbold T.J., Nachbagauer R., Xu H., Tan G.S., Hirsh A., Brokstad K.A., et al. Vaccination with adjuvanted recombinant neuraminidase induces broad heterologous, but not heterosubtypic, cross-protection against influenza virus infection in mice. MBio 2015, 6:e02556. 10.1128/mBio.02556-14.
13. Giudice G., Hilbert A., Bugarini R., Minutello A., Popova O., Toneatto D., et al. An MF59-adjuvanted inactivated influenza vaccine containing A/Panama/1999 (H3N2) induced broader serological protection against heterovariant influenza virus strain A/Fujian/2002 than a subunit and a split influenza vaccine. Vaccine 2006, 24:3063-3065. 10.1016/j.vaccine.2006.01.015.
14. Nohynek H., Jokinen J., Partinen M., Vaarala O., Kirjavainen T., Sundman J., et al. AS03 adjuvanted AH1N1 vaccine associated with an abrupt increase in the incidence of childhood narcolepsy in Finland. PLoS ONE 2012, 7:e33536. 10.1371/journal.pone.0033536.
15. Rouleau I., De Serres G., Drolet J.P., Skowronski D.M., Ouakki M., Toth E., et al. Increased risk of anaphylaxis following administration of 2009 AS03-adjuvanted monovalent pandemic A/H1N1 (H1N1pdm09) vaccine. Vaccine 2013, 31:5989-5996. 10.1016/j.vaccine.2013.10.033.
16. ® vaccine against H7N9 influenza is immunogenic in mice. Emerg Microbes Infect 2013, 2:e52. 10.1038/emi.2013.54.
17. Langley J.M., Frenette L., Ferguson L., Riff D., Sheldon E., Risi G., et al. Safety and cross-reactive immunogenicity of candidate AS03-adjuvanted prepandemic H5N1 influenza vaccines: a randomized controlled phase 1/2 trial in adults. J Infect Dis 2010, 201:1644-1653. 10.1086/652701.
18. Krammer F., Palese P., Steel J. Advances in universal influenza virus vaccine design and antibody mediated therapies based on conserved regions of the hemagglutinin. Curr Top Microbiol Immunol 2015, 386:301-321. 10.1007/82_2014_408.
19. Cummings J.F., Guerrero M.L., Moon J.E., Waterman P., Nielsen R.K., Jefferson S., et al. Safety and immunogenicity of a plant-produced recombinant monomer hemagglutinin-based influenza vaccine derived from influenza A (H1N1)pdm09 virus: a Phase 1 dose-escalation study in healthy adults. Vaccine 2014, 32:2251-2259. 10.1016/j.vaccine.2013.10.017.
20. Atsmon J., Caraco Y., Ziv-Sefer S., Shaikevich D., Abramov E., Volokhov I., et al. Priming by a novel universal influenza vaccine (Multimeric-001) - a gateway for improving immune response in the elderly population. Vaccine 2014, 32:5816-5823. 10.1016/j.vaccine.2014.08.031.
21. Stoloff G.A., Caparros-Wanderley W. Synthetic multi-epitope peptides identified in silico induce protective immunity against multiple influenza serotypes. Eur J Immunol 2007, 37:2441-2449. 10.1002/eji.200737254.
22. Mössler C., Groiss F., Wolzt M., Wolschek M., Seipelt J., Muster T. Phase I/II trial of a replication-deficient trivalent influenza virus vaccine lacking NS1. Vaccine 2013, 31:6194-6200. 10.1016/j.vaccine.2013.10.061.
23. De Filette M., Martens W., Smet A., Schotsaert M., Birkett A., Londoño-Arcila P., et al. Universal influenza A M2e-HBc vaccine protects against disease even in the presence of pre-existing anti-HBc antibodies. Vaccine 2008, 26:6503-6507. 10.1016/j.vaccine.2008.09.038.
24. Yan J., Villarreal D.O., Racine T., Chu J.S., Walters J.N., Morrow M.P., et al. Protective immunity to H7N9 influenza viruses elicited by synthetic DNA vaccine. Vaccine 2014, 32:2833-2842. 10.1016/j.vaccine.2014.02.038.
25. Lambe T., Carey J.B., Li Y., Spencer A.J., van Laarhoven A., Mullarkey C.E., et al. Immunity against heterosubtypic influenza virus induced by adenovirus and MVA expressing nucleoprotein and matrix protein-1. Sci Rep 2013, 3:1443. 10.1038/srep01443.
26. Kanekiyo M., Wei C.-J., Yassine H.M., McTamney P.M., Boyington J.C., Whittle J.R.R., et al. Self-assembling influenza nanoparticle vaccines elicit broadly neutralizing H1N1 antibodies. Nature 2013, 499:102-106. 10.1038/nature12202.
27. Altenburg A.F., Kreijtz J.H.C.M., de Vries R.D., Song F., Fux R., Rimmelzwaan G.F., et al. Modified vaccinia virus ankara (MVA) as production platform for vaccines against influenza and other viral respiratory diseases. Viruses 2014, 6:2735-2761. 10.3390/v6072735.
28. Schmitz N., Beerli R.R., Bauer M., Jegerlehner A., Dietmeier K., Maudrich M., et al. Universal vaccine against influenza virus: linking TLR signaling to anti-viral protection. Eur J Immunol 2012, 42:863-869. 10.1002/eji.201041225.
29. Zhou D., Wu T.-L., Lasaro M.O., Latimer B.P., Parzych E.M., Bian A., et al. A universal influenza A vaccine based on adenovirus expressing matrix-2 ectodomain and nucleoprotein protects mice from lethal challenge. Mol Ther 2010, 18:2182-2189. 10.1038/mt.2010.202.
30. Furuya Y., Chan J., Regner M., Lobigs M., Koskinen A., Kok T., et al. Cytotoxic T cells are the predominant players providing cross-protective immunity induced by -irradiated influenza A viruses. J Virol 2010, 84:4212-4221. 10.1128/JVI.02508-09.
31. Crevar C.J., Carter D.M., Lee K.Y.J., Ross T.M. Cocktail of H5N1 COBRA HA vaccines elicit protective antibodies against H5N1 viruses from multiple clades. Hum Vaccin Immunother 2015, 11:572-583. 10.1080/21645515.2015.1012013.
32. Pena L., Sutton T., Chockalingam A., Kumar S., Angel M., Shao H., et al. Influenza viruses with rearranged genomes as live-attenuated vaccines. J Virol 2013, 87:5118-5127. 10.1128/JVI.02490-12.
33. Kallen K.-J., Heidenreich R., Schnee M., Petsch B., Schlake T., Thess A., et al. A novel, disruptive vaccination technology. Hum Vaccin Immunother 2014, 9:2263-2276. 10.4161/hv.25181.
34. Limberis M.P., Adam V.S., Wong G., Gren J., Kobasa D., Ross T.M., et al. Intranasal antibody gene transfer in mice and ferrets elicits broad protection against pandemic influenza. Sci Transl Med 2013, 5:187ra72. 10.1126/scitranslmed.3006299.
35. Kim M.-C., Song J.-M., O E., Kwon Y.-M., Lee Y.-J., Compans R.W., et al. Virus-like particles containing multiple M2 extracellular domains confer improved cross-protection against various subtypes of influenza virus. Mol Ther 2012, 21:485-492. 10.1038/mt.2012.246.
36. Fu T.-M., Grimm K.M., Citron M.P., Freed D.C., Fan J., Keller P.M., et al. Comparative immunogenicity evaluations of influenza A virus M2 peptide as recombinant virus like particle or conjugate vaccines in mice and monkeys. Vaccine 2009, 27:1440-1447. 10.1016/j.vaccine.2008.12.034.
37. Florek N.W., Weinfurter J.T., Jegaskanda S., Brewoo J.N., Powell T.D., Young G.R., et al. Modified vaccinia virus Ankara encoding influenza virus hemagglutinin induces heterosubtypic immunity in macaques. J Virol 2014, 88:13418-13428. 10.1128/JVI.01219-14.
38. Yang C., Skiena S., Futcher B., Mueller S., Wimmer E. Deliberate reduction of hemagglutinin and neuraminidase expression of influenza virus leads to an ultraprotective live vaccine in mice. Proc Natl Acad Sci U S A 2013, 110:9481-9486. 10.1073/pnas.1307473110.
39. Vitelli A., Quirion M.R., Lo C.-Y., Misplon J.A., Grabowska A.K., Pierantoni A., et al. Vaccination to conserved influenza antigens in mice using a novel simian adenovirus vector, PanAd3, derived from the bonobo pan paniscus. PLOS ONE 2013, 8:e55435. 10.1371/journal.pone.0055435.
40. De Filette M., Martens W., Roose K., Deroo T., Vervalle F., Bentahir M., et al. An influenza A vaccine based on tetrameric ectodomain of matrix protein 2. J Biol Chem 2008, 283:11382-11387. 10.1074/jbc.M800650200.
41. Eliasson D.G., El Bakkouri K., Schön K., Ramne A., Festjens E., Löwenadler B., et al. CTA1-M2e-DD: a novel mucosal adjuvant targeted influenza vaccine. Vaccine 2008, 26:1243-1252. 10.1016/j.vaccine.2007.12.027.
42. Liu W., Li H., Chen Y.-H. N-terminus of M2 protein could induce antibodies with inhibitory activity against influenza virus replication. FEMS Immunol Med Microbiol 2003, 35:141-146.
43. Fan X., Hashem A.M., Chen Z., Li C., Doyle T., Zhang Y., et al. Targeting the HA2 subunit of influenza A virus hemagglutinin via CD40L provides universal protection against diverse subtypes. Mucosal Immunol 2015, 8:211-220. 10.1038/mi.2014.59.
44. Balazs A.B., Bloom J.D., Hong C.M., Rao D.S., Baltimore D. Broad protection against influenza infection by vectored immunoprophylaxis in mice. Nat Biotechnol 2013, 31:647-652. 10.1038/nbt.2618.